Dear Madam, Sir,

On 16/09/2011 you have been granted a Belgian national authorization to place on the Belgian market the following biocidal product:

**BIOBAN™ GA 24 Antimicrobial**

authorization number NOTIF562.

In view of the pending Union Authorization application submitted to the European Chemical Agency on 20/09/2016 and according to the transitional measures as laid out in article 89, §2 of the Biocidal Product Regulation (EU) No 528/2012 we can provide you with a prolongation of making your product **BIOBAN™ GA 24 Antimicrobial** available on the Belgian market until 3 years after the date of approval of the last active substances to be approved in this given biocidal product. **Your product may remain on the Belgian market**, under the same conditions as those mentioned in the Belgian authorization NOTIF562, and at the latest until 01/10/2019.

This letter is the **official notification of the new date of validity** of the mentioned Belgian authorization NOTIF562. The biocidal product concerned will continue to be included in the list of the authorized biocidal products, which can be found at [www.biocide.be](http://www.biocide.be). The already granted authorization will not be amended. You can use this letter as proof of the validity of the existing authorization.
This letter remains **valid until the Union Authorization** is granted and will terminate on 01/10/2019 at the latest. The granted Union Authorization will provide a period of grace to continue to market the biocidal product concerned with the current authorization number NOTIF562 (180 days for the making available on the Belgian market and an additional maximum period of 180 days). If the Commission shall adopt an implementing decision stating that the Union Authorization has not been granted, the biocidal product concerned will no longer be made available on the market 180 days after the implementing regulation has been adopted. The use of existing stocks remains authorized until a maximum of 365 days after the date of adoption of the Commission decision.

Best regards,

A. Rihoux